Companies HCA Healthcare, Inc.
HCA Healthcare (HCA): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me HCA Healthcare, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers67th pct.Of 24 peer CEOs
CEO pay, last three years
- $21,315,984FY2023
- $23,799,137FY2024
- $26,456,606FY2025
CEO total pay was $26,456,606 in fiscal 2025, up from $23,799,137 in fiscal 2024.
FY2025: salary $1,577,815 · bonus $0 · stock awards $8,474,543 · option awards $8,514,090
Executives and directors
Jon Foster · COOMichael Cuffe · EVPMichael Marks · CFOMichael McAlevey · General CounselSamuel Hazen · CEOAndrea B. Smith · Independent DirectorHugh F. Johnston · Independent DirectorJohn W. Chidsey, III · Independent DirectorMeg G. Crofton · Former director (through FY2025)Michael W. Michelson · Independent DirectorNancy-Ann DeParle · Independent DirectorRobert J. Dennis · Independent DirectorThomas F. Frist III · Chair of the BoardWayne J. Riley, M.D · Independent DirectorWilliam R. Frist · Director
Frequently asked questions
Who was the highest-paid executive at HCA Healthcare, Inc. in fiscal 2025?
As disclosed, Samuel Hazen (Chief Executive Officer) was the highest-paid executive at HCA Healthcare, Inc. in fiscal 2025, with total compensation of $26,456,606.
How does HCA Healthcare, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Samuel Hazen's total compensation ranked at the 67th percentile of HCA Healthcare, Inc.'s disclosed peer group.
What is HCA Healthcare, Inc.'s CEO-to-median employee pay ratio?
As disclosed, HCA Healthcare, Inc.'s CEO-to-median employee pay ratio was 420:1.
How did shareholders vote on HCA Healthcare, Inc.'s executive compensation?
As disclosed, 93.46% of shareholders supported HCA Healthcare, Inc.'s executive compensation in the latest say-on-pay vote.
How much does HCA Healthcare, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, HCA Healthcare, Inc. reported total board compensation of $3,406,839 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Samuel Hazen | $1,577,815 | $0 | $8,474,543 | $8,514,090 | $5,416,732 | $1,934,400 | $539,026 | $26,456,606 |
| Chief Executive Officer | ||||||||
| Jon Foster | 1,043,375 | 0 | 1,903,173 | 1,911,848 | 2,558,549 | 3,422,029 | 153,812 | 10,992,786 |
| Executive Vice President and Chief Operating Officer | ||||||||
| Michael Marks | 982,500 | 0 | 1,776,295 | 1,784,399 | 2,422,729 | 3,305,382 | 83,806 | 10,355,111 |
| Executive Vice President and Chief Financial Officer | ||||||||
| Michael McAlevey | 1,012,688 | 0 | 1,268,782 | 1,274,603 | 1,986,638 | 0 | 167,624 | 5,710,335 |
| Executive Vice President - Chief Legal and Administrative Officer | ||||||||
| Michael Cuffe | 974,834 | 0 | 1,268,782 | 1,274,603 | 1,918,606 | 0 | 267,372 | 5,704,197 |
| Executive Vice President and Chief Clinical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Samuel Hazen | $26,456,606 | $23,799,137 | $21,315,984 | ↑ +2,657,469 |
| Jon Foster | 10,992,786 | — | 8,699,360 | — |
| Michael Marks | 10,355,111 | 5,509,371 | — | ↑ +4,845,740 |
| Michael McAlevey | 5,710,335 | — | — | — |
| Michael Cuffe | 5,704,197 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The core philosophy of our executive compensation program is to support the Company s primary objective of providing high-quality health care to our patients, while making a positive impact on the communities in which we operate and enhancing the long-term value of the Company for our stockholders.
| CEO STI target (% of salary) | 175% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Semler Brossy |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Jon Foster | PSU | 2025-01-28 | 1,447 | 5,790 | — | 11,580 | $1,903,173 |
| Michael McAlevey | OPTION | 2025-01-28 | — | — | 11,171 | — | 1,274,603 |
| Michael Cuffe | PSU | 2025-01-28 | 965 | 3,860 | — | 7,720 | 1,268,782 |
| Michael Marks | PSU | 2025-01-28 | 1,351 | 5,404 | — | 10,808 | 1,776,295 |
| Samuel Hazen | PSU | 2025-01-28 | 6,445 | 25,782 | — | 51,564 | 8,474,543 |
| Michael McAlevey | PSU | 2025-01-28 | 965 | 3,860 | — | 7,720 | 1,268,782 |
| Michael Cuffe | OPTION | 2025-01-28 | — | — | 11,171 | — | 1,274,603 |
| Michael Marks | OPTION | 2025-01-28 | — | — | 15,639 | — | 1,784,399 |
| Jon Foster | OPTION | 2025-01-28 | — | — | 16,756 | — | 1,911,848 |
| Samuel Hazen | OPTION | 2025-01-28 | — | — | 74,620 | — | 8,514,090 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Jon Foster | $0 | $1,903,173 | $1,911,848 | 49.9% |
| Michael McAlevey | 0 | 1,268,782 | 1,274,603 | 49.9% |
| Michael Cuffe | 0 | 1,268,782 | 1,274,603 | 49.9% |
| Michael Marks | 0 | 1,776,295 | 1,784,399 | 49.9% |
| Samuel Hazen | 0 | 8,474,543 | 8,514,090 | 49.9% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Michael McAlevey | PSU | 788 | — | $367,886 |
| Michael Marks | SAR | 1,040 | 236.61 | — |
| Michael McAlevey | SAR | 1,706 | 311.42 | — |
| Michael Marks | PSU | 1,905 | — | 889,368 |
| Michael Marks | PSU | 3,149 | — | 1,470,142 |
| Michael McAlevey | SAR | 3,465 | 236.61 | — |
| Michael Marks | SAR | 3,789 | 253.3 | — |
| Michael McAlevey | PSU | 3,810 | — | 1,778,737 |
| Michael Cuffe | SAR | 3,813 | 236.61 | — |
| Michael McAlevey | PSU | 3,860 | — | 1,802,080 |
| Michael Cuffe | PSU | 3,860 | — | 1,802,080 |
| Michael Marks | SAR | 4,128 | 304.9 | — |
| Michael Cuffe | PSU | 4,382 | — | 2,045,781 |
| Jon Foster | SAR | 4,505 | 236.61 | — |
| Michael Marks | PSU | 5,404 | — | 2,522,911 |
| Jon Foster | PSU | 5,790 | — | 2,703,119 |
| Michael McAlevey | SAR | 6,315 | 253.3 | — |
| Michael Marks | SAR | 6,822 | 311.42 | — |
| Jon Foster | PSU | 7,144 | — | 3,335,248 |
| Michael Cuffe | SAR | 7,262 | 253.3 | — |
| Michael McAlevey | SAR | 8,254 | 304.9 | — |
| Michael Cuffe | SAR | 9,492 | 304.9 | — |
| Michael McAlevey | SAR | 11,171 | 328.7 | — |
| Michael Cuffe | SAR | 11,171 | 328.7 | — |
| Jon Foster | SAR | 11,840 | 253.3 | — |
| Jon Foster | SAR | 15,476 | 304.9 | — |
| Michael Marks | SAR | 15,639 | 328.7 | — |
| Jon Foster | SAR | 16,756 | 328.7 | — |
| Samuel Hazen | SAR | 21,658 | 236.61 | — |
| Samuel Hazen | PSU | 25,782 | — | 12,036,585 |
| Samuel Hazen | PSU | 27,622 | — | 12,895,607 |
| Samuel Hazen | SAR | 41,440 | 253.3 | — |
| Samuel Hazen | SAR | 59,838 | 304.9 | — |
| Samuel Hazen | SAR | 74,620 | 328.7 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Thomas F. Frist IIINot independent · Board Chair · Finance and Investments | $229,892 | $219,674 | $0 | $0 | $0 | $449,566 |
| Michael W. MichelsonIndependent · Audit and Compliance · Compensation · Finance and Investments (Chair) | 212,725 | 219,674 | 0 | 0 | 0 | 432,399 |
| Hugh F. JohnstonIndependent · Audit and Compliance (Chair) · Nominating and Corporate Governance | 197,673 | 219,674 | 0 | 0 | 0 | 417,347 |
| Wayne J. Riley, M.DIndependent · Audit and Compliance · Nominating and Corporate Governance · Patient Safety and Quality of Care | 156,580 | 219,674 | 0 | 0 | 0 | 376,254 |
| Andrea B. SmithIndependent · Audit and Compliance · Compensation (Chair) | 151,841 | 219,674 | 0 | 0 | 0 | 371,515 |
| Nancy-Ann DeParleIndependent · Nominating and Corporate Governance · Patient Safety and Quality of Care | 151,841 | 219,674 | 0 | 0 | 0 | 371,515 |
| Robert J. DennisIndependent · Compensation · Not standing for re-election | 143,978 | 219,674 | 0 | 0 | 0 | 363,652 |
| William R. FristNot independent · Finance and Investments · Patient Safety and Quality of Care | 132,920 | 219,674 | 0 | 0 | 0 | 352,594 |
| John W. Chidsey, IIIIndependent · Audit and Compliance · Compensation · Newly elected | 60,054 | 170,872 | 0 | 0 | 0 | 230,926 |
| Meg G. CroftonIndependent · Departed during FY | 41,071 | — | 0 | 0 | 0 | 41,071 |
| Samuel N. HazenEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $130,000 |
|---|---|
| Annual equity retainer | $220,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 30,000 / 25,000 / 25,000 |
| Stock ownership guideline | he Board of Directors within five years from the date on which they are elected to the Board of Directors. As of December 31, 2019, all of our directors with more than five years of service met these share ownership guidelines. |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $1,478,575 |
| Equity awards (grant-date value) | $1,928,264 |
| All other compensation | $0 |
| Total cost of the board | $3,406,839 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names HCA Healthcare as a peer
Companies that benchmark against HCA
14 companies name HCA as a compensation peer
The list of companies that name HCA as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
MRK Merck & Co., Inc.MCK McKesson CorporationCAH Cardinal Health, Inc.THC Tenet Healthcare CorporationUNH UnitedHealth Group IncorporatedTMO Thermo Fisher Scientific Inc.ELV Elevance Health, Inc.GILD Gilead Sciences, Inc.ABBV AbbVie Inc.SYK Stryker CorporationCNC Centene Corp.CVS CVS Health CorporationAMGN Amgen Inc.DHR Danaher CorporationMDT Medtronic Inc.ABT Abbott LaboratoriesBMY Bristol-Myers Squibb CompanyCOR Cencora, Inc.LLY Eli Lilly and CompanyHUM Humana Inc.JNJ Johnson & JohnsonMOH Molina Healthcare, Inc.PFE Pfizer Inc.CI The Cigna Group
Peer reciprocity
The companies HCA Healthcare, Inc. names as compensation peers that name it back in their own disclosed peer groups.
Tenet Healthcare Corporation (THC)81Centene Corp. (CNC)82Cencora, Inc. (COR)83Humana Inc. (HUM)84Molina Healthcare, Inc. (MOH)85The Cigna Group (CI)86
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific Inc. | 2025 | Marc Casper | $1,785,534 | $65,730,211 | $7,951,377 | $3,742,123 | $79,923,350 |
| 2 | UnitedHealth Group Incorporated | 2025 | Stephen Hemsley | 596,154 | 0 | 60,000,024 | 0 | 60,938,062 |
| 3 | Tenet Healthcare Corporation | 2025 | Saum Sutaria | 1,500,000 | 31,677,365 | 0 | 9,000,000 | 43,108,969 |
| 4 | Eli Lilly and Company | 2025 | David Ricks | 1,700,000 | 23,325,000 | 0 | 6,485,500 | 36,698,337 |
| 5 | Johnson & Johnson | 2025 | Joaquin Duato | 1,600,000 | 15,028,948 | 5,927,995 | 4,298,700 | 32,758,111 |
| 6 | AbbVie Inc. | 2025 | Robert Michael | 1,700,000 | 13,268,456 | 3,199,154 | 5,200,000 | 32,530,984 |
| 7 | Gilead Sciences, Inc. | 2025 | Daniel O'Day | 1,795,192 | 15,238,402 | 4,500,060 | 4,848,120 | 28,437,198 |
| 8 | Pfizer Inc. | 2025 | Albert Bourla | 1,800,000 | 9,442,705 | 8,998,141 | 5,400,000 | 27,585,301 |
| 9 | HCA Healthcare, Inc. | 2025 | Samuel Hazen | 1,577,815 | 8,474,543 | 8,514,090 | 5,416,732 | 26,456,606 |
| 10 | Amgen Inc. | 2025 | Robert Bradway | 1,925,409 | 12,599,589 | 5,399,996 | 3,907,000 | 24,693,120 |
| 11 | McKesson Corporation | 2026 | Brian Tyler | 1,591,667 | 17,201,202 | 0 | 4,456,668 | 24,213,044 |
| 12 | Abbott Laboratories | 2025 | Robert Ford | 1,500,000 | 8,787,378 | 8,788,430 | 1,968,750 | 24,198,660 |
| 13 | Danaher Corporation | 2025 | Rainer Blair | 1,400,000 | 9,292,370 | 8,386,657 | 4,194,400 | 23,795,280 |
| 14 | Medtronic Inc. | 2026 | Geoffrey Martha | 1,399,039 | 13,672,200 | 5,175,559 | 2,307,200 | 22,940,252 |
| 15 | The Cigna Group | 2025 | David Cordani | 1,600,000 | 13,929,161 | 3,400,019 | 3,200,000 | 22,866,134 |
| 16 | Elevance Health, Inc. | 2025 | Gail Boudreaux | 1,600,000 | 13,440,277 | 4,199,765 | 2,768,000 | 22,582,314 |
| 17 | Cardinal Health, Inc. | 2026 | Jason Hollar | 1,500,000 | 16,259,918 | 0 | 4,278,750 | 22,574,349 |
| 18 | Bristol-Myers Squibb Company | 2025 | Christopher Boerner | 1,586,346 | 16,061,399 | 0 | 3,754,684 | 21,879,919 |
| 19 | Stryker Corporation | 2025 | Kevin Lobo | 1,500,000 | 9,764,136 | 6,920,781 | 2,250,000 | 21,401,495 |
| 20 | CVS Health Corporation | 2025 | J. David Joyner | 1,500,000 | 14,499,931 | 0 | 4,695,900 | 21,214,084 |
| 21 | Merck & Co., Inc. | 2025 | Robert Davis | 1,645,302 | 12,102,838 | 3,380,004 | 2,326,500 | 20,797,845 |
| 22 | Centene Corp. | 2025 | Sarah London | 1,473,077 | 15,537,733 | 0 | 2,109,446 | 19,506,298 |
| 23 | Humana Inc. | 2025 | James Rechtin | 1,348,558 | 13,868,141 | 0 | 3,034,740 | 18,757,075 |
| 24 | Molina Healthcare, Inc. | 2025 | Joseph Zubretsky | 1,600,000 | 16,199,988 | 0 | 0 | 18,340,783 |
| 25 | Cencora, Inc. | 2025 | Robert Mauch | 1,350,000 | 12,000,218 | 0 | 4,283,213 | 18,256,227 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| HCA Healthcare, Inc. | 195.78% | SAR 50 · PSU 50 | No | Semler Brossy |
| Abbott Laboratories | 75.0% | Options 50 · PSU 50 | No | Meridian Compensation Partners, LLC |
| AbbVie Inc. | not disclosed | PSU 40 · PRSU 40 · Option 20 | Yes — Relative TSR | Semler Brossy |
| Amgen Inc. | 136.0% | PSU 50 · Options 30 · RSU 20 | Yes — relative TSR | Frederic W. Cook & Co., Inc. (FW Cook) |
| Bristol-Myers Squibb Company | 157.66% | PSU 60 · MSU 40 | Yes — 3-Year Relative TSR CAGR | Farient Advisors LLC |
| Cardinal Health, Inc. | not disclosed | PSU 60 · RSU 40 | Yes — Relative TSR modifier | Korn Ferry |
| Cencora, Inc. | 181.3% | PSU 60 · RSU 40 | Yes — Relative TSR | Pearl Meyer & Partners |
| Centene Corp. | 71.6% | PSU 60 · RSU 40 | Yes — Relative TSR | FW Cook |
| CVS Health Corporation | 156.5% | PSU 60 · RSU 20 · Options 20 | Yes — rTSR Modifier | Korn Ferry |
| Danaher Corporation | not disclosed | Options 50 · RSU 50 | Yes — Relative TSR | FW Cook |
| Elevance Health, Inc. | 86.5% | PSU 52 · RSU 24 · Options 24 | No | Willis Towers Watson (WTW) |
| Eli Lilly and Company | 218% | PSU 100 | No | FW Cook |
| Gilead Sciences, Inc. | 180% | PSU 50 · Option 25 · RSU 25 | Yes — Relative TSR | FW Cook |
| Humana Inc. | 112% | PSU 60 · RSU 40 | Yes — Relative TSR | Farient Advisors, LLC |
| Johnson & Johnson | not disclosed | not disclosed | Yes — Relative TSR | Semler Brossy Consulting Group |
| McKesson Corporation | 140% | PSU 60 · RSU 40 | Yes — Total Shareholder Return (TSR) relative to comparator group | Korn Ferry |
| Medtronic Inc. | 103% | PSU 50 · Options 30 · RSU 20 | No | Semler Brossy |
| Merck & Co., Inc. | 94% | PSU 60 · RSU 20 · Options 20 | Yes — Relative Total Shareholder Return (R-TSR) | FW Cook |
| Molina Healthcare, Inc. | not disclosed | PSU 60 · RSU 40 | No | FW Cook |
| Pfizer Inc. | 150% | PSU 50 · MSU 50 | Yes — relative TSR as compared to the NYSE Arca Pharmaceutical Index (DRG Index or DRG) | Meridian Compensation Partners, LLC |
| Stryker Corporation | 100% | PSU 48 · Options 34 | No | Semler Brossy |
| Tenet Healthcare Corporation | 200% | PSU 60 · RSU 40 | No | Meridian Compensation Partners, LLC |
| The Cigna Group | 100% | PSU 60 · RSU 20 · Options 20 | No | Pay Governance |
| Thermo Fisher Scientific Inc. | 99.8% | PSU 50 · Options 50 | Yes — Relative TSR | Pearl Meyer |
| UnitedHealth Group Incorporated | not disclosed | PSU 50 · Options 25 · RSU 25 | No | Pay Governance |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-04-23 | 182,386,619 | 12,758,446 | 289,073 | 93.46% | Passed |
| 2025 | 2025-04-24 | 198,712,163 | 13,569,145 | 173,653 | 93.61% | Passed |
| 2024 | 2024-04-25 | 217,056,657 | 13,495,544 | 98,729 | 94.15% | Passed |
| 2023 | 2023-04-19 | 230,579,766 | 10,927,402 | 298,429 | 95.48% | Passed |
| 2022 | 2022-04-21 | 245,696,830 | 14,385,360 | 384,640 | 94.47% | Passed |
| 2021 | 2021-04-28 | 280,813,046 | 10,403,853 | 953,807 | 96.43% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-04-23 | 93.46%a |
| 2025 | 2025-04-24 | 93.61%b |
| 2024 | 2024-04-25 | 94.15%c |
a. Approved under the standard stated in the filing — “If you abstain from voting on Proposal 1, your abstention will have no effect on the outcome.”.
b. Approved under the standard stated in the filing — “If you abstain from voting on Proposal 1, your abstention will have no effect on the outcome.”.
c. Approved under the standard stated in the filing — “If you abstain from voting on Proposal 1, your abstention will have no effect on the outcome.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 420 : 1 |
|---|---|
| CEO total compensation | $26,456,606 |
| Median employee compensation | $62,955 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| John W. Chidsey, III | Director | 2026-04-28 | A | 809 | $0 | $0 | Common | Form 4 ↗ |
| Nancy-Ann DeParle | Director | 2026-04-28 | A | 509 | 0 | 0 | Common | Form 4 ↗ |
| Andrea B. Smith | Director | 2026-04-28 | A | 509 | 0 | 0 | Common | Form 4 ↗ |
| Wayne Joseph Riley | Director | 2026-04-28 | A | 509 | 0 | 0 | Common | Form 4 ↗ |
| Thomas F. Frist III | Director | 2026-04-28 | A | 1,041 | 0 | 0 | Common | Form 4 ↗ |
| William R. Frist | Director | 2026-04-28 | A | 809 | 0 | 0 | Common | Form 4 ↗ |
| Hugh F. Johnston | Director | 2026-04-28 | A | 809 | 0 | 0 | Common | Form 4 ↗ |
| Michael W. Michelson | Director | 2026-04-28 | A | 925 | 0 | 0 | Common | Form 4 ↗ |
| Michael Marks | EVP and CFO | 2026-05-07 | D | 3,336 | 0 | 0 | Common | Form 4 ↗ |
| Michael Marks | EVP and CFO | 2026-05-07 | A | 3,336 | 0 | 0 | Common | Form 4 ↗ |
| Michael McAlevey | EVP & Chief Legal & Admin Off. | 2026-08-26 | D | 7,769 | 429 | 3,332,901 | Common | Form 4 ↗ |
| Michael J. Schlosser | EVP and Chief Clinical Officer | 2026-10-29 | A | 2,797 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-10-29 | — | 1,898 | — | — | 1 insider, 1 accrual row | ||
| Michael J. Schlosser | EVP and Chief Clinical Officer | 2026-10-29 | D | 3,030 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael J. Schlosser | EVP and Chief Clinical Officer | 2026-10-29 | D | 2,455 | 478 | 1,173,686 | Common | Form 4 ↗ |
| Michael J. Schlosser | EVP and Chief Clinical Officer | 2026-10-29 | A | 1,898 | 83 | 157,249 | Common | Form 4 ↗ |
| Michael J. Schlosser | EVP and Chief Clinical Officer | 2026-10-29 | A | 3,030 | 82 | 248,339 | Common | Form 4 ↗ |
| Michael Marks | EVP and CFO | 2026-10-30 | D | 4,585 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Marks | EVP and CFO | 2026-10-30 | D | 2,287 | 473 | 1,082,186 | Common | Form 4 ↗ |
| Michael Marks | EVP and CFO | 2026-10-30 | A | 4,585 | 82 | 375,787 | Common | Form 4 ↗ |
| Michael Marks | EVP and CFO | 2026-11-02 | D | 1,042 | 0 | 0 | Common | Form 4 ↗ |
| Michael Marks | EVP and CFO | 2026-11-02 | D | 1,042 | 469 | 489,120 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 22 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| John W. Chidsey, III | Director | 2026-04-28 | A | 809 | $0 | $0 | Common | Form 4 ↗ |
| Nancy-Ann DeParle | Director | 2026-04-28 | A | 509 | 0 | 0 | Common | Form 4 ↗ |
| Andrea B. Smith | Director | 2026-04-28 | A | 509 | 0 | 0 | Common | Form 4 ↗ |
| Wayne Joseph Riley | Director | 2026-04-28 | A | 509 | 0 | 0 | Common | Form 4 ↗ |
| Thomas F. Frist III | Director | 2026-04-28 | A | 1,041 | 0 | 0 | Common | Form 4 ↗ |
| William R. Frist | Director | 2026-04-28 | A | 809 | 0 | 0 | Common | Form 4 ↗ |
| Hugh F. Johnston | Director | 2026-04-28 | A | 809 | 0 | 0 | Common | Form 4 ↗ |
| Michael W. Michelson | Director | 2026-04-28 | A | 925 | 0 | 0 | Common | Form 4 ↗ |
| Michael Marks | EVP and CFO | 2026-05-07 | D | 3,336 | 0 | 0 | Common | Form 4 ↗ |
| Michael Marks | EVP and CFO | 2026-05-07 | A | 3,336 | 0 | 0 | Common | Form 4 ↗ |
| Michael McAlevey | EVP & Chief Legal & Admin Off. | 2026-08-26 | D | 7,769 | 429 | 3,332,901 | Common | Form 4 ↗ |
| Michael J. Schlosser | EVP and Chief Clinical Officer | 2026-10-29 | A | 2,797 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael J. Schlosser | EVP and Chief Clinical Officer | 2026-10-29 | D | 1,898 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael J. Schlosser | EVP and Chief Clinical Officer | 2026-10-29 | D | 3,030 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael J. Schlosser | EVP and Chief Clinical Officer | 2026-10-29 | D | 2,455 | 478 | 1,173,686 | Common | Form 4 ↗ |
| Michael J. Schlosser | EVP and Chief Clinical Officer | 2026-10-29 | A | 1,898 | 83 | 157,249 | Common | Form 4 ↗ |
| Michael J. Schlosser | EVP and Chief Clinical Officer | 2026-10-29 | A | 3,030 | 82 | 248,339 | Common | Form 4 ↗ |
| Michael Marks | EVP and CFO | 2026-10-30 | D | 4,585 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Marks | EVP and CFO | 2026-10-30 | D | 2,287 | 473 | 1,082,186 | Common | Form 4 ↗ |
| Michael Marks | EVP and CFO | 2026-10-30 | A | 4,585 | 82 | 375,787 | Common | Form 4 ↗ |
| Michael Marks | EVP and CFO | 2026-11-02 | D | 1,042 | 0 | 0 | Common | Form 4 ↗ |
| Michael Marks | EVP and CFO | 2026-11-02 | D | 1,042 | 469 | 489,120 | Common | Form 4 ↗ |
Sources (86 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Samuel Hazen. DEF 14A, filed 2026-03-13. Section “2025 Summary Compensation Table” · page 75. As printed: 26,456,606. View filing ↗
- Section 01, Jon Foster. DEF 14A, filed 2026-03-13. Section “2025 Summary Compensation Table” · page 75. As printed: 10,992,786. View filing ↗
- Section 01, Michael Marks. DEF 14A, filed 2026-03-13. Section “2025 Summary Compensation Table” · page 75. As printed: 10,355,111. View filing ↗
- Section 01, Michael McAlevey. DEF 14A, filed 2026-03-13. Section “2025 Summary Compensation Table” · page 75. As printed: 5,710,335. View filing ↗
- Section 01, Michael Cuffe. DEF 14A, filed 2026-03-13. Section “2025 Summary Compensation Table” · page 75. As printed: 5,704,197. View filing ↗
- Section 03, Jon Foster PSU. DEF 14A, filed 2026-03-13. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Michael McAlevey OPTION. DEF 14A, filed 2026-03-13. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Cuffe PSU. DEF 14A, filed 2026-03-13. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Marks PSU. DEF 14A, filed 2026-03-13. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Samuel Hazen PSU. DEF 14A, filed 2026-03-13. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Michael McAlevey PSU. DEF 14A, filed 2026-03-13. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Cuffe OPTION. DEF 14A, filed 2026-03-13. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Marks OPTION. DEF 14A, filed 2026-03-13. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Jon Foster OPTION. DEF 14A, filed 2026-03-13. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Samuel Hazen OPTION. DEF 14A, filed 2026-03-13. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-03-13. Section “CEO Pay Ratio”. As printed: 420 : 1. View filing ↗
- Section 08, Thomas F. Frist III. DEF 14A, filed 2026-03-13. Section “Director Compensation”. As printed: 449,566. View filing ↗
- Section 08, Michael W. Michelson. DEF 14A, filed 2026-03-13. Section “Director Compensation”. As printed: 432,399. View filing ↗
- Section 08, Hugh F. Johnston. DEF 14A, filed 2026-03-13. Section “Director Compensation”. As printed: 417,347. View filing ↗
- Section 08, Wayne J. Riley, M.D. DEF 14A, filed 2026-03-13. Section “Director Compensation”. As printed: 376,254. View filing ↗
- Section 08, Andrea B. Smith. DEF 14A, filed 2026-03-13. Section “Director Compensation”. As printed: 371,515. View filing ↗
- Section 08, Nancy-Ann DeParle. DEF 14A, filed 2026-03-13. Section “Director Compensation”. As printed: 371,515. View filing ↗
- Section 08, Robert J. Dennis. DEF 14A, filed 2026-03-13. Section “Director Compensation”. As printed: 363,652. View filing ↗
- Section 08, William R. Frist. DEF 14A, filed 2026-03-13. Section “Director Compensation”. As printed: 352,594. View filing ↗
- Section 08, John W. Chidsey, III. DEF 14A, filed 2026-03-13. Section “Director Compensation”. As printed: 230,926. View filing ↗
- Section 08, Meg G. Crofton. DEF 14A, filed 2026-03-13. Section “Director Compensation”. As printed: 41,071. View filing ↗
- Section 08, Samuel N. Hazen. DEF 14A, filed 2026-03-13. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, John W. Chidsey, III 2026-04-28. Form 4, filed 2026-04-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nancy-Ann DeParle 2026-04-28. Form 4, filed 2026-04-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrea B. Smith 2026-04-28. Form 4, filed 2026-04-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Wayne Joseph Riley 2026-04-28. Form 4, filed 2026-04-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas F. Frist III 2026-04-28. Form 4, filed 2026-04-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William R. Frist 2026-04-28. Form 4, filed 2026-04-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hugh F. Johnston 2026-04-28. Form 4, filed 2026-04-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael W. Michelson 2026-04-28. Form 4, filed 2026-04-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Marks 2026-05-07. Form 4, filed 2026-05-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Marks 2026-05-07. Form 4, filed 2026-05-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael McAlevey 2026-08-26. Form 4, filed 2026-08-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael J. Schlosser 2026-10-29. Form 4, filed 2026-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael J. Schlosser 2026-10-29. Form 4, filed 2026-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael J. Schlosser 2026-10-29. Form 4, filed 2026-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael J. Schlosser 2026-10-29. Form 4, filed 2026-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael J. Schlosser 2026-10-29. Form 4, filed 2026-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael J. Schlosser 2026-10-29. Form 4, filed 2026-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Marks 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Marks 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Marks 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Marks 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Marks 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-04-28. Item 5.07 · say-on-pay result. As reported: 93.46% (votes for as printed: 182,386,619). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-04-29. Item 5.07 · say-on-pay result. As reported: 93.61% (votes for as printed: 198,712,163). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-04-30. Item 5.07 · say-on-pay result. As reported: 94.15% (votes for as printed: 217,056,657). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 1,478,575 + equity 1,928,264 + all other 0 = 3,406,839, summed across the director compensation table rows.
- Thermo Fisher Scientific Inc., Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Thermo Fisher Scientific Inc.'s own proxy. As printed: 79,923,350. View filing ↗
- UnitedHealth Group Incorporated, Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in UnitedHealth Group Incorporated's own proxy. As printed: 60,938,062. View filing ↗
- Tenet Healthcare Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Tenet Healthcare Corporation's own proxy. As printed: 43,108,969. View filing ↗
- Eli Lilly and Company, Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in Eli Lilly and Company's own proxy. As printed: 36,698,337. View filing ↗
- Johnson & Johnson, Section 10b CEO total. DEF 14A, filed 2026-03-11. CEO total compensation as printed in Johnson & Johnson's own proxy. As printed: 32,758,111. View filing ↗
- AbbVie Inc., Section 10b CEO total. DEF 14A, filed 2026-03-23. CEO total compensation as printed in AbbVie Inc.'s own proxy. As printed: 32,530,984. View filing ↗
- Gilead Sciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in Gilead Sciences, Inc.'s own proxy. As printed: 28,437,198. View filing ↗
- Pfizer Inc., Section 10b CEO total. DEF 14A, filed 2026-03-12. CEO total compensation as printed in Pfizer Inc.'s own proxy. As printed: 27,585,301. View filing ↗
- HCA Healthcare, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-03-13. CEO total compensation as printed in HCA Healthcare, Inc.'s own proxy. As printed: 26,456,606. View filing ↗
- Amgen Inc., Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Amgen Inc.'s own proxy. As printed: 24,693,120. View filing ↗
- McKesson Corporation, Section 10b CEO total. DEF 14A, filed 2026-06-12. CEO total compensation as printed in McKesson Corporation's own proxy. As printed: 24,213,044. View filing ↗
- Abbott Laboratories, Section 10b CEO total. DEF 14A, filed 2026-03-13. CEO total compensation as printed in Abbott Laboratories's own proxy. As printed: 24,198,660. View filing ↗
- Danaher Corporation, Section 10b CEO total. DEF 14A, filed 2026-03-25. CEO total compensation as printed in Danaher Corporation's own proxy. As printed: 23,795,280. View filing ↗
- Medtronic Inc., Section 10b CEO total. DEF 14A, filed 2026-08-17. CEO total compensation as printed in Medtronic Inc.'s own proxy. As printed: 22,940,252. View filing ↗
- The Cigna Group, Section 10b CEO total. DEF 14A, filed 2026-03-13. CEO total compensation as printed in The Cigna Group's own proxy. As printed: 22,866,134. View filing ↗
- Elevance Health, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-27. CEO total compensation as printed in Elevance Health, Inc.'s own proxy. As printed: 22,582,314. View filing ↗
- Cardinal Health, Inc., Section 10b CEO total. DEF 14A, filed 2026-09-21. CEO total compensation as printed in Cardinal Health, Inc.'s own proxy. As printed: 22,574,349. View filing ↗
- Bristol-Myers Squibb Company, Section 10b CEO total. DEF 14A, filed 2026-03-25. CEO total compensation as printed in Bristol-Myers Squibb Company's own proxy. As printed: 21,879,919. View filing ↗
- Stryker Corporation, Section 10b CEO total. DEF 14A, filed 2026-03-23. CEO total compensation as printed in Stryker Corporation's own proxy. As printed: 21,401,495. View filing ↗
- CVS Health Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-03. CEO total compensation as printed in CVS Health Corporation's own proxy. As printed: 21,214,084. View filing ↗
- Merck & Co., Inc., Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Merck & Co., Inc.'s own proxy. As printed: 20,797,845. View filing ↗
- Centene Corp., Section 10b CEO total. DEF 14A, filed 2026-03-26. CEO total compensation as printed in Centene Corp.'s own proxy. As printed: 19,506,298. View filing ↗
- Humana Inc., Section 10b CEO total. DEFR 14A, filed 2026-03-06. CEO total compensation as printed in Humana Inc.'s own proxy. As printed: 18,757,075. View filing ↗
- Molina Healthcare, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-23. CEO total compensation as printed in Molina Healthcare, Inc.'s own proxy. As printed: 18,340,783. View filing ↗
- Cencora, Inc., Section 10b CEO total. DEF 14A, filed 2026-01-22. CEO total compensation as printed in Cencora, Inc.'s own proxy. As printed: 18,256,227. View filing ↗
- Section 10a, Tenet Healthcare Corporation reciprocity. DEF 14A. Tenet Healthcare Corporation names HCA Healthcare, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Centene Corp. reciprocity. DEF 14A. Centene Corp. names HCA Healthcare, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Cencora, Inc. reciprocity. DEF 14A. Cencora, Inc. names HCA Healthcare, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Humana Inc. reciprocity. DEF 14A. Humana Inc. names HCA Healthcare, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Molina Healthcare, Inc. reciprocity. DEF 14A. Molina Healthcare, Inc. names HCA Healthcare, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, The Cigna Group reciprocity. DEF 14A. The Cigna Group names HCA Healthcare, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗